GIP and steatosis: Moreover, it should be acknowledged that novel pharmacotherapeutic interventions which promote weight loss including the glucagon-like peptide 1 (GLP-1) receptor and gastric inhibitory polypeptide (GIP) agonists hold promise in reducing steatosis of possible donors [21].